BlackRock Inc. raised its position in shares of Pfenex Inc (NYSEAMERICAN:PFNX) by 257.1% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,316,873 shares of the biotechnology company’s stock after buying an additional 948,102 shares during the quarter. BlackRock Inc. owned about 0.06% of Pfenex worth $7,125,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in PFNX. Rhumbline Advisers acquired a new stake in shares of Pfenex during the 2nd quarter worth approximately $103,000. Algert Global LLC acquired a new stake in shares of Pfenex during the 2nd quarter worth approximately $154,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Pfenex during the 2nd quarter worth approximately $216,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Pfenex by 94.3% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 62,833 shares of the biotechnology company’s stock worth $340,000 after purchasing an additional 30,488 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of Pfenex by 142.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 68,390 shares of the biotechnology company’s stock worth $370,000 after purchasing an additional 40,175 shares during the period.
In other Pfenex news, insider Evert B. Schimmelpennink acquired 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 11th. The stock was acquired at an average cost of $5.04 per share, with a total value of $50,400.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Phillip M. Schneider acquired 11,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 11th. The stock was acquired at an average cost of $4.99 per share, with a total value of $54,890.00. The disclosure for this purchase can be found here. Insiders purchased a total of 26,000 shares of company stock valued at $129,540 over the last three months.
A number of brokerages have recently weighed in on PFNX. Zacks Investment Research upgraded Pfenex from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research report on Wednesday, October 10th. William Blair reiterated an “outperform” rating on shares of Pfenex in a research report on Monday, September 10th.
Shares of Pfenex stock opened at $4.42 on Wednesday. Pfenex Inc has a twelve month low of $2.07 and a twelve month high of $8.42.
Pfenex (NYSEAMERICAN:PFNX) last issued its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). The company had revenue of $4.19 million during the quarter, compared to analyst estimates of $5.55 million.
COPYRIGHT VIOLATION NOTICE: “BlackRock Inc. Increases Holdings in Pfenex Inc (PFNX)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/11/07/blackrock-inc-increases-holdings-in-pfenex-inc-pfnx.html.
Pfenex Inc, a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company's lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that are in Phase I study.
Read More: Book Value Per Share in Stock Trading
Want to see what other hedge funds are holding PFNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfenex Inc (NYSEAMERICAN:PFNX).
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.